This HTML5 document contains 163 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n5http://linked.opendata.cz/resource/AHFS/
n20http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/national-drug-code-directory/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n7http://linked.opendata.cz/resource/drugbank/mixture/
n22http://www.drugs.com/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/chemspider/
n28http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n27http://www.rxlist.com/cgi/generic/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/pharmgkb/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/wikipedia/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/kegg-compound/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/pubchem-compound/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00191/identifier/drugbank/
n31http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00191
rdf:type
n3:Drug
n3:description
A central nervous system stimulant and sympathomimetic with actions and uses similar to those of dextroamphetamine. It has been used most frequently in the treatment of obesity. [PubChem]. Some common brand names for phentermine are Adipex-P® and Suprenza™. Phentermine is also available in combination medications such as Qsymia®.
n3:dosage
n26:271B55FA-363D-11E5-9242-09173F13E4C5 n26:271B55FB-363D-11E5-9242-09173F13E4C5 n26:271B55FC-363D-11E5-9242-09173F13E4C5 n26:271B55FD-363D-11E5-9242-09173F13E4C5 n26:271B55F7-363D-11E5-9242-09173F13E4C5 n26:271B55F8-363D-11E5-9242-09173F13E4C5 n26:271B55F9-363D-11E5-9242-09173F13E4C5 n26:271B55FE-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Bray GA: A concise review on the therapeutics of obesity. Nutrition. 2000 Oct;16(10):953-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11054601 # Nelson DL, Gehlert DR: Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006 Feb;29(1):49-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16622292
n3:group
illicit approved
n3:halfLife
16 to 31 hours
n3:indication
For the treatment and management of obesity.
n3:manufacturer
n20:271B55D1-363D-11E5-9242-09173F13E4C5 n20:271B55D2-363D-11E5-9242-09173F13E4C5 n20:271B55CF-363D-11E5-9242-09173F13E4C5 n20:271B55D0-363D-11E5-9242-09173F13E4C5 n20:271B55D5-363D-11E5-9242-09173F13E4C5 n20:271B55D6-363D-11E5-9242-09173F13E4C5 n20:271B55D3-363D-11E5-9242-09173F13E4C5 n20:271B55D4-363D-11E5-9242-09173F13E4C5 n20:271B55D9-363D-11E5-9242-09173F13E4C5 n20:271B55DA-363D-11E5-9242-09173F13E4C5 n20:271B55D7-363D-11E5-9242-09173F13E4C5 n20:271B55D8-363D-11E5-9242-09173F13E4C5 n20:271B55DD-363D-11E5-9242-09173F13E4C5 n20:271B55DE-363D-11E5-9242-09173F13E4C5 n20:271B55DB-363D-11E5-9242-09173F13E4C5 n20:271B55DC-363D-11E5-9242-09173F13E4C5 n20:271B55E1-363D-11E5-9242-09173F13E4C5 n20:271B55E2-363D-11E5-9242-09173F13E4C5 n20:271B55DF-363D-11E5-9242-09173F13E4C5 n20:271B55E0-363D-11E5-9242-09173F13E4C5 n20:271B55E5-363D-11E5-9242-09173F13E4C5 n20:271B55E6-363D-11E5-9242-09173F13E4C5 n20:271B55E3-363D-11E5-9242-09173F13E4C5 n20:271B55E4-363D-11E5-9242-09173F13E4C5 n20:271B55E9-363D-11E5-9242-09173F13E4C5 n20:271B55EA-363D-11E5-9242-09173F13E4C5 n20:271B55E7-363D-11E5-9242-09173F13E4C5 n20:271B55E8-363D-11E5-9242-09173F13E4C5 n20:271B55EB-363D-11E5-9242-09173F13E4C5
owl:sameAs
n25:DB00191 n28:DB00191
dcterms:title
Phentermine
adms:identifier
n13:4607 n14:DB00191 n15:8080 n16:D05458 n17:0527-1445-01 n18:C07438 n19:46508515 n23:4771 n29:PA164748099 n30:Phentermine
n3:mechanismOfAction
Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse.Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.
n3:packager
n20:271B55CD-363D-11E5-9242-09173F13E4C5 n20:271B55CE-363D-11E5-9242-09173F13E4C5 n20:271B55CB-363D-11E5-9242-09173F13E4C5 n20:271B55CC-363D-11E5-9242-09173F13E4C5 n20:271B55C9-363D-11E5-9242-09173F13E4C5 n20:271B55CA-363D-11E5-9242-09173F13E4C5 n20:271B55C7-363D-11E5-9242-09173F13E4C5 n20:271B55C8-363D-11E5-9242-09173F13E4C5 n20:271B55C5-363D-11E5-9242-09173F13E4C5 n20:271B55C6-363D-11E5-9242-09173F13E4C5 n20:271B55C3-363D-11E5-9242-09173F13E4C5 n20:271B55C4-363D-11E5-9242-09173F13E4C5 n20:271B55C1-363D-11E5-9242-09173F13E4C5 n20:271B55C2-363D-11E5-9242-09173F13E4C5 n20:271B55BF-363D-11E5-9242-09173F13E4C5 n20:271B55C0-363D-11E5-9242-09173F13E4C5 n20:271B55BD-363D-11E5-9242-09173F13E4C5 n20:271B55BE-363D-11E5-9242-09173F13E4C5 n20:271B55BB-363D-11E5-9242-09173F13E4C5 n20:271B55BC-363D-11E5-9242-09173F13E4C5 n20:271B55B9-363D-11E5-9242-09173F13E4C5 n20:271B55BA-363D-11E5-9242-09173F13E4C5 n20:271B55B7-363D-11E5-9242-09173F13E4C5 n20:271B55B8-363D-11E5-9242-09173F13E4C5 n20:271B55B5-363D-11E5-9242-09173F13E4C5 n20:271B55B6-363D-11E5-9242-09173F13E4C5 n20:271B55A1-363D-11E5-9242-09173F13E4C5 n20:271B55B3-363D-11E5-9242-09173F13E4C5 n20:271B55A2-363D-11E5-9242-09173F13E4C5 n20:271B55B4-363D-11E5-9242-09173F13E4C5 n20:271B55B1-363D-11E5-9242-09173F13E4C5 n20:271B55A0-363D-11E5-9242-09173F13E4C5 n20:271B55B2-363D-11E5-9242-09173F13E4C5 n20:271B55AF-363D-11E5-9242-09173F13E4C5 n20:271B55B0-363D-11E5-9242-09173F13E4C5 n20:271B55AD-363D-11E5-9242-09173F13E4C5 n20:271B55AE-363D-11E5-9242-09173F13E4C5 n20:271B55AB-363D-11E5-9242-09173F13E4C5 n20:271B55AC-363D-11E5-9242-09173F13E4C5 n20:271B55A9-363D-11E5-9242-09173F13E4C5 n20:271B55AA-363D-11E5-9242-09173F13E4C5 n20:271B55A7-363D-11E5-9242-09173F13E4C5 n20:271B55A8-363D-11E5-9242-09173F13E4C5 n20:271B55A5-363D-11E5-9242-09173F13E4C5 n20:271B55A6-363D-11E5-9242-09173F13E4C5 n20:271B55A3-363D-11E5-9242-09173F13E4C5 n20:271B55A4-363D-11E5-9242-09173F13E4C5
n3:synonym
Fentermina Phenterminum alpha,alpha-Dimethylphenethylamine
n3:toxicity
LD<sub>50</sub> is adult monkeys is 15 to 20 mg/kg. Symptoms of overdose include delirium, mania, self-injury, marked hypertension, tachycardia, arrhythmia, hyperpyrexia, convulsion, coma, and circulatory collapse.
n4:hasAHFSCode
n5:28-20-92
n3:foodInteraction
Limit caffeine intake. Take without regard to meals.
n3:mixture
n7:271B559E-363D-11E5-9242-09173F13E4C5 n7:271B559F-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Approximately 96.3%
n3:salt
n10:hasConcept
n11:M0016536
foaf:page
n22:phentermine.html n27:phenterm.htm
n3:IUPAC-Name
n6:271B5603-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5609-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5608-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B5605-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B5606-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B5607-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5601-363D-11E5-9242-09173F13E4C5 n6:271B5618-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B55FF-363D-11E5-9242-09173F13E4C5 n6:271B561A-363D-11E5-9242-09173F13E4C5 n6:271B5602-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5600-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n31:A08AA01
n3:H-Bond-Acceptor-Count
n6:271B560F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5610-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B560A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B560B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B560D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B560C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B560E-363D-11E5-9242-09173F13E4C5
n3:absorption
Phentermine is rapidly absorbed after oral ingestion.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
122-09-8
n3:category
n3:containedIn
n8:271B55F4-363D-11E5-9242-09173F13E4C5 n8:271B55F5-363D-11E5-9242-09173F13E4C5 n8:271B55F2-363D-11E5-9242-09173F13E4C5 n8:271B55F3-363D-11E5-9242-09173F13E4C5 n8:271B55F0-363D-11E5-9242-09173F13E4C5 n8:271B55F1-363D-11E5-9242-09173F13E4C5 n8:271B55EE-363D-11E5-9242-09173F13E4C5 n8:271B55EF-363D-11E5-9242-09173F13E4C5 n8:271B55EC-363D-11E5-9242-09173F13E4C5 n8:271B55ED-363D-11E5-9242-09173F13E4C5 n8:271B55F6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B5614-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B5616-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5617-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5619-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5613-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5612-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B5615-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5604-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5611-363D-11E5-9242-09173F13E4C5